VNDA - バンダ・ファ―マシュ―ティカルズ (Vanda Pharmaceuticals Inc.) バンダ・ファ―マシュ―ティカルズ

 VNDAのチャート


 VNDAの企業情報

symbol VNDA
会社名 Vanda Pharmaceuticals Inc (バンダ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バンダ・ファーマシューティカルズ(Vanda Pharmaceuticals Inc.)は生物医薬品会社である。同社は、満たされていない医療ニーズに対応する治療法の開発・商品化を行う。同社の製品ポートフォリオには、HETLIOZ(tasimelteon)、Fanapt(iloperidone)、Tradipitant(VLY-686)、Trichostatin AおよびAQW051がある。同社は非24時間睡眠覚醒障害(24歳未満)の治療にHETLIOZを提供する。HETLIOZは、Pediatric Non-24、Jet Lag DisorderおよびSmith-Magenis症候群の治療用の臨床開発中である。同社は統合失調症の治療用のFanaptを提供する。Fanaptは、多様な他の障害において有用性がある。Tradipitantは、小分子ニューロキニン-1受容体(NK-1R)アンタゴニストであり、アトピー性皮膚炎における慢性掻痒の治療のための臨床開発中である。トリコスタチンAは、小分子ヒストンデアセチラーゼ(HDAC)阻害剤である。AQW051は、第II相アルファ-7ニコチン性アセチルコリン受容体部分アゴニストである。AQW051は、中枢神経系障害の治療に適応する。   バンダ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。中枢神経系障害の治療用の薬品を開発、商業化する。主要な製品には、24時間睡眠覚醒障害の治療用に「HETLIOZ」、統合失調症の治療用に「Fanapt」、アトピ―性皮膚炎の治療用に小分子ニュ―ロキニン-1受容体拮抗薬「VLY-686」などがある。   Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
本社所在地 2200 Pennsylvania Avenue N.W. Suite 300 E Washington DC 20037 USA
代表者氏名 H. Thomas Watkins H.トーマス・ワトキンス
代表者役職名 Independent Chairman of the Board
電話番号 +1 202-734-3400
設立年月日 37561
市場名 NASDAQ National Market System
ipoyear 2006年
従業員数 273人
url www.vandapharma.com
nasdaq_url https://www.nasdaq.com/symbol/vnda
adr_tso
EBITDA EBITDA(百万ドル) 2.28300
終値(lastsale) 23
時価総額(marketcap) 1204727235
時価総額 時価総額(百万ドル) 1123.539
売上高 売上高(百万ドル) 176.55400
企業価値(EV) 企業価値(EV)(百万ドル) 892.32300
当期純利益 当期純利益(百万ドル) 1.28900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vanda Pharmaceuticals Inc. revenues increased 14% to $90.9M. Net income totaled $7.7M vs. loss of $9.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Selling General and administrative - decrease of 14% to $49.5M (expense) Other income increase from $677K to $1.4M (income).

 VNDAのテクニカル分析


 VNDAのニュース

   Looking Into Vanda Pharmaceuticals''s Return On Capital Employed  2022/08/10 13:52:17 Benzinga
According to Benzinga Pro, during Q2, Vanda Pharmaceuticals (NASDAQ: VNDA ) earned $2.57 million, a 140.03% increase from the preceding quarter. Vanda Pharmaceuticals also posted a total of $64.39 million in sales, a 6.97% increase since Q1. Vanda Pharmaceuticals collected $60.19 million in revenue during Q1, but reported earnings showed a $6.43 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. … Full story available on Benzinga.com
   Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2022 Results - Earnings Call Transcript  2022/08/03 22:42:10 Seeking Alpha
Vanda Pharmaceuticals Inc. (NASDAQ:NASDAQ:VNDA) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Mihael H.
   Vanda Pharmaceuticals GAAP EPS of $0.05, revenue of $64.39M  2022/08/03 20:03:54 Seeking Alpha
Vanda Pharmaceuticals press release (VNDA): Q2 GAAP EPS of $0.05.Revenue of $64.39M.Guidance: Total revenues $240 to $280 million. Consensus Revenue Estimate for 2022 is $265.10M
   Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results  2022/08/03 20:01:00 PR Newswire
Q2 2022 total revenues were $64.4 million Total revenues in the first six months of 2022 were $124.6 million Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON, Aug. 3, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced…
   Vanda Pharmaceuticals Q2 Earnings Preview (NASDAQ:VNDA)  2022/08/02 16:53:24 Seeking Alpha
Vanda Pharmaceuticals (VNDA) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close.The consensus EPS Estimate is $0.12 (-29.4% Y/Y) and the…
   Shareholder Alert: Robbins LLP Announces that Vanda Pharmaceuticals Inc. (VNDA) Class Action Survives Motion to Dismiss  2021/03/11 18:52:00 Business Wire
SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending securities lawsuit. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders. If you suffered a loss as a result of Vanda's misconduct, click here. Shareholder Class Action Alleging Vanda Pharmaceuticals
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $107,865.72 in Stock  2021/02/21 11:40:57 Watchlist News
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Thomas Watkins sold 5,818 shares of the firm’s stock in a transaction that occurred on Tuesday, February 16th. The shares were sold at an average price of $18.54, for a total transaction of $107,865.72. Following the transaction, the director now directly owns 55,323 shares in the company, valued at approximately […]
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   Return On Capital Employed Overview: Vanda Pharmaceuticals  2021/02/11 10:28:00 Benzinga
Looking at Q4, Vanda Pharmaceuticals (NASDAQ:VNDA) earned $10.45 million, a 34.99% increase from the preceding quarter. Vanda Pharmaceuticals also posted a …
   Shareholder Alert: Robbins LLP Announces that Vanda Pharmaceuticals Inc. (VNDA) Class Action Survives Motion to Dismiss  2021/03/11 18:52:00 Business Wire
SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending securities lawsuit. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders. If you suffered a loss as a result of Vanda's misconduct, click here. Shareholder Class Action Alleging Vanda Pharmaceuticals
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $107,865.72 in Stock  2021/02/21 11:40:57 Watchlist News
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Thomas Watkins sold 5,818 shares of the firm’s stock in a transaction that occurred on Tuesday, February 16th. The shares were sold at an average price of $18.54, for a total transaction of $107,865.72. Following the transaction, the director now directly owns 55,323 shares in the company, valued at approximately […]
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   Return On Capital Employed Overview: Vanda Pharmaceuticals  2021/02/11 10:28:00 Benzinga
Looking at Q4, Vanda Pharmaceuticals (NASDAQ:VNDA) earned $10.45 million, a 34.99% increase from the preceding quarter. Vanda Pharmaceuticals also posted a …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バンダ・ファ―マシュ―ティカルズ VNDA Vanda Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)